Compare Flux Power Holdings Inc (FLUX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Novo Nordisk A/S — how do they compare? Flux Power Holdings Inc trades at $0.61 (market cap $11.23M), while Novo Nordisk A/S trades at $46.25 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 18508.5× Flux Power Holdings Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals.
| FLUX | NVO | |
|---|---|---|
Market Cap | $11.23M | $207.85B |
Sector | Utilities | Health |
52-Week High | $6.66 | $63.98 |
52-Week Low | $0.51 | $35.29 |
Enterprise Value | $17.39M | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.5408, up 3.21% today, but technical indicators signal a bearish trend with selling pressure across moving averages. The company reported revenue of $66.43M in 2025 but a net loss of $6.67M, with profitability metrics like ROE at -52.27% reflecting operational challenges. Recent news highlights product launches like SkyEMS 3.0 and an upcoming earnings call on August 20, 2026.
Despite unanimous analyst buy ratings, FLUX faces significant risks from persistent losses and negative cash flow projections. Investment appeal hinges on execution of growth initiatives in lithium-ion storage, but high volatility and competitive pressures warrant caution for equity investors.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
